Literature DB >> 20584752

OX40 ligand plays an important role in the development of atherosclerosis through vasa vasorum neovascularization.

Makoto Nakano1, Yoshihiro Fukumoto, Kimio Satoh, Yoshitaka Ito, Yutaka Kagaya, Naoto Ishii, Kazuo Sugamura, Hiroaki Shimokawa.   

Abstract

AIMS: Atherosclerosis is characterized by infiltration of inflammatory cells and enhanced vasa vasorum formation, for which immunological mechanisms may be involved. OX40, a membrane-bound molecule of the tumour necrosis factor-receptor superfamily, is expressed by activated T-cells, while OX40 ligand (OX40L) is expressed in activated macrophages and endothelial cells. In this study, we thus examined whether the OX40/OX40L system is involved in the pathogenesis of atherosclerosis. METHODS AND
RESULTS: We examined apolipoprotein E-deficient (ApoE(-/-)) mice and ApoE(-/-)/OX40L-double-deficient (ApoE(-/-)/OX40L(-/-)) mice fed on a high-fat diet for 8 weeks. The extent of aortic atheroma was significantly less in ApoE(-/-)/OX40L(-/-) mice compared with ApoE(-/-) mice. We also treated high-fat-fed ApoE(-/-) mice with or without MGP34 antibody (OX40L-specific neutralizing antibody) for 10 weeks. After the treatment, the extent of aortic atheroma was again significantly less in MGP34-treated mice compared with controls. Importantly, both vascular density in the aortic adventitia and vascular endothelial growth factor-induced angiogenesis in the Matrigel assay in vivo were significantly reduced in ApoE(-/-)/OX40L(-/-) mice compared with ApoE(-/-) mice. Finally, when high-fat-fed ApoE(-/-) mice were transplanted with bone marrow cells from either wild-type or OX40L(-/-) mice, the extent of aortic atheroma was comparable between the two groups.
CONCLUSION: These results indicate that the vascular OX40/OX40L system plays an important role in the formation of vasa vasorum and subsequent atherosclerosis, suggesting that the vascular OX40/OX40L system might be a new therapeutic target of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20584752     DOI: 10.1093/cvr/cvq211

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  18 in total

Review 1.  Potential contributions of intimal and plaque hypoxia to atherosclerosis.

Authors:  Guo-Hua Fong
Journal:  Curr Atheroscler Rep       Date:  2015-06       Impact factor: 5.113

Review 2.  Immune effector mechanisms implicated in atherosclerosis: from mice to humans.

Authors:  Peter Libby; Andrew H Lichtman; Göran K Hansson
Journal:  Immunity       Date:  2013-06-27       Impact factor: 31.745

3.  Technical advance: soluble OX40 molecule mimics regulatory T cell modulatory activity on FcεRI-dependent mast cell degranulation.

Authors:  Riccardo Sibilano; Giorgia Gri; Barbara Frossi; Claudio Tripodo; Ryo Suzuki; Juan Rivera; Andrew S MacDonald; Carlo E Pucillo
Journal:  J Leukoc Biol       Date:  2011-06-07       Impact factor: 4.962

Review 4.  Innate and adaptive immunity: the understudied driving force of heart valve disease.

Authors:  Francesca Bartoli-Leonard; Jonas Zimmer; Elena Aikawa
Journal:  Cardiovasc Res       Date:  2021-11-22       Impact factor: 10.787

5.  Effects of OX40-OX40L interaction on the nuclear factor of activated T cells c1 in ApoE-deficient mice.

Authors:  Jin-chuan Yan; Liang-jie Xu; Cui-ping Wang; Zhong-qun Wang
Journal:  Inflammation       Date:  2014-02       Impact factor: 4.092

6.  Effect of rosuvastatin on OX40L and PPAR-γ expression in human umbilical vein endothelial cells and atherosclerotic cerebral infarction patients.

Authors:  Jing-Yu Zhang; Bin Liu; Ya-Nan Wang; Wei-Na Zhang; Feng-Jun Wang
Journal:  J Mol Neurosci       Date:  2013-10-27       Impact factor: 3.444

Review 7.  The dynamic lives of macrophage and dendritic cell subsets in atherosclerosis.

Authors:  Parésa L Taghavie-Moghadam; Matthew J Butcher; Elena V Galkina
Journal:  Ann N Y Acad Sci       Date:  2014-03-14       Impact factor: 5.691

8.  Clinical implications of tenascin-C and OX40 ligand in patients with acute coronary syndrome.

Authors:  Jin-Hu Yang; Feng Ren
Journal:  Biomed Rep       Date:  2013-11-04

Review 9.  T cell co-stimulation and co-inhibition in cardiovascular disease: a double-edged sword.

Authors:  Karin H Simons; Alwin de Jong; J Wouter Jukema; Margreet R de Vries; Ramon Arens; Paul H A Quax
Journal:  Nat Rev Cardiol       Date:  2019-06       Impact factor: 32.419

Review 10.  Immune checkpoint proteins: exploring their therapeutic potential to regulate atherosclerosis.

Authors:  A C Foks; J Kuiper
Journal:  Br J Pharmacol       Date:  2017-05-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.